What is Autoimmunity BioSolutions?
Autoimmunity BioSolutions is a specialized biotechnology enterprise dedicated to the development of next-generation precision immunotherapies. The company operates at the intersection of genetic insights and therapeutic innovation, focusing on the modulation of specific immune pathways to restore homeostasis in patients suffering from chronic autoimmune diseases. By utilizing a biomarker-driven framework, the firm creates personalized treatment protocols that target the root causes of immune dysfunction rather than merely managing symptoms. This methodology represents a significant shift in the therapeutic landscape, moving away from traditional, non-specific immunosuppressive treatments toward highly refined, genetically targeted interventions that promise improved safety profiles and superior clinical outcomes for specific patient populations.
How much funding has Autoimmunity BioSolutions raised?
Autoimmunity BioSolutions has raised a total of $3.1M across 1 funding round:
Seed
$3.1M
Seed (2026): $3.1M with participation from Independent Capital Group and Eos BioInnovation, LLC
Key Investors in Autoimmunity BioSolutions
Independent Capital Group
Independent Capital Group AG is a multi-family office and investment firm that specializes in systematic, long-term risk-adjusted capital allocation for high-net-worth clients.
Eos BioInnovation, LLC
EOS Bioinnovation is a specialized biotechnology firm focused on advancing biological research and sustainable bio-based solutions within the life sciences sector.
What's next for Autoimmunity BioSolutions?
With the recent influx of capital, Autoimmunity BioSolutions is poised to scale its research and development operations significantly. The strategic roadmap likely includes the expansion of clinical trial infrastructure and the refinement of its lead therapeutic candidates. As the company moves deeper into the development lifecycle, the focus will shift toward validating its biomarker-driven platform in larger patient cohorts and establishing key partnerships within the pharmaceutical industry. This phase of growth is critical for demonstrating the long-term efficacy and scalability of their precision medicine model, ultimately aiming to secure a dominant position in the evolving market for autoimmune therapeutics.
See full Autoimmunity BioSolutions company page
